GMP IPO Watch
Sai Parenteral’s IPO Day 3: A High-Premium Pharma Play—Steady Progress or Overvalued?
Hyderabad-based Sai Parenteral's enters the final stretch of its ₹409 crore IPO. With a price band of ₹372–₹392 and a focus on high-margin injectables, the company is pitching a massive growth story. However, with a ₹0 GMP and a high P/E ratio, we break down the Day 3 subscription and the "Long-Term vs. Listing Gain" debate.
Live IPO tracking available
Check GMP movement, allotment details, subscription demand, and deeper IPO context for this company.
Use these shortcuts to keep exploring
The archive button opens all articles from this category. The IPO details button opens the live IPO page on your GMP site in a new tab.
1. Live Status: Subscription Update (March 26, 11:30 AM)
After a slow start on Day 1, the momentum picked up slightly on Day 2. As of this morning:
Total Subscription: Approximately 0.42x to 0.45x.
NII (HNI) Interest: This segment is leading the way, currently subscribed around 1.05x, showing that larger individual investors are seeing value in the CDMO (Contract Manufacturing) model.
Retail Portion: Currently lagging at 0.05x. Retail investors seem to be staying cautious due to the lack of a listing premium.
Grey Market (GMP): Currently trading at ₹0. This suggests a flat listing (around ₹392), making it less attractive for those seeking a quick "flip."
2. The Business: The Injectable Edge
Sai Parenteral's isn't just making basic tablets. They are specialized in Sterile Injectables and Critical Care.
Global Footprint: They recently made a major move by acquiring Noumed Pharmaceuticals in Australia, giving them direct access to highly regulated markets like Australia and New Zealand.
CDMO Focus: A significant portion of their business is helping other pharma giants develop and manufacture their drugs, a segment known for high "stickiness" and better margins.
Therapeutic Range: They cover high-demand areas like cardiovascular, anti-diabetic, and neuropsychiatry.
3. IPO Snapshot & Timeline
| Event / Detail | Important Dates & Info |
|---|---|
| IPO Closing Date | Friday, March 27, 2026 |
| Price Band | ₹372 to ₹392 per share |
| Lot Size | 38 Shares |
| Retail Min. Investment | ₹14,896 (1 Lot) |
| Allotment Date | Monday, March 30, 2026 |
| Listing Date | Thursday, April 2, 2026 (NSE & BSE) |
4. Financials: Rapid Growth vs. High Price
The numbers tell a story of a company in a "sprint" phase:
Revenue Growth: Revenue surged from ₹97 crore (FY23) to ₹163.74 crore (FY25).
Margins: EBITDA margins are healthy, standing at 24.18%, which is competitive for the pharma manufacturing sector.
The "Valuation" Catch: At the upper price band, the IPO is valued at a P/E of ~72x. This is significantly higher than established peers like Gland Pharma (~46x) or Innova Captab (~37x). Investors are essentially paying today for the growth expected 2–3 years down the line.
5. The Verdict: Pros & Cons
The Bull Case (The "Pros"):
Strategic Expansion: The Australia/New Zealand acquisition provides a "fast track" into regulated western markets.
High-Margin Niche: Injectables are harder to manufacture than tablets, creating a natural barrier to entry for smaller competitors.
Fresh Capital: ₹111 crore of the proceeds is going into capacity expansion, which will be the primary driver for future revenue.
The Bear Case (The "Cons"):
Expensive Valuation: The 72x P/E ratio leaves very little "margin of safety" for investors if the company misses its growth targets.
Negative Cash Flow: The company has reported negative operating cash flows recently due to high inventory and working capital needs.
Zero Listing Gains: With the GMP at ₹0, this is strictly a long-term play; short-term gains are unlikely.
